20.03.2014 Geratherm Medical AG  DE0005495626

DGAP-Adhoc: Geratherm Medical AG: Geratherm Medical announces business figures for


 
Geratherm Medical AG / Key word(s): Final Results 20.03.2014 13:32 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a company of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- DGAP Ad hoc announcement: Geratherm Medical announces business figures for 2013 Ad hoc announcement in compliance with Section 15 of the Securities Trading Act (Wertpapierhandelsgesetz, WpHG) communicated via DGAP - a company of the Equity Story Group. The content of the communication is the responsibility of the issuer. Geratherm Medical announces business figures for 2013 - Turnover EUR 16.8 million +5.4 % - Healthcare Diagnostic +0.5 %, Patient Warming Systems +15.9 %, Respiratory +28.1 %, Cardio/Stroke +72.1 % - EBITDA 1,601 kEUR -6.6 % - EBIT 793 kEUR -17.1 % - Operating and exchange-rate related losses by Geratherm do Brasil had a negative effect on the operating result amounting to -337 kEUR (previous year: +163 kEUR) - Financial result +492 kEUR (+0.1 %) - Result from the general course of business 1,285 kEUR (-11.3 %) - Result for the shareholders (EAT) 1,334 kEUR (+11.7 %) - Result per share 27 cents (previous year: 24 cents) - Proposed dividend 24 cents per share (previous year: 20 cents) - Equity capital 20.1 million EUR (+7.8 %), 4.06 EUR per share - Liquid funds and securities 15.5 million EUR (+23.4 %) Geschwenda, 20 March 2014 - At its meeting today, the Supervisory Board approved the annual accounts and the consolidated accounts as at 31 December 2013. The annual accounts have therefore been adopted. The Supervisory Board approved the Managing Board's proposal regarding the use of the balance sheet profits, which provides for a dividend of 24 cents per share. In contrast to previous years, capital gains tax and solidarity surcharge on the proposed dividend amount are to be retained. According to the tax regulations, the distributable profits from the business year must be used first and only then the tax deposit account. For the business year 2013, the distributable profits amount to 1,913 kEUR and will not be completely used up as a result of the planned dividend distribution, so that access to the tax deposit account, on which 15,206 kEUR are still held, is not possible. Out of the full distributable amount of 1,188 kEUR, capital gains tax and solidarity surcharge equivalent to 26.38 % must therefore be retained. If, in future years, dividend distributions exceed the applicable distributable profits, these can continue to be paid tax-free out of the tax deposit account. The date for publication of the detailed business report has been brought forward to 16 April 2014 (instead of 24 April 2014). Short company profil: Geratherm Medical is an internationally operating medical products enterprise with the business areas Healthcare Diagnostic, Medical Warming Systems, Cardio/Stroke and Respiratory. Our company's roots are in temperature measurement in the medical sphere. In this business area we offer a broad spectrum of products, most of which have unique selling points. We supply our customers/patients with high-quality products ranging from thermometers to complex warming systems for use in the operating theatre and by emergency rescue services. In the Cardio business area we concentrate on the development of products for the detection of atrial fibrillation as a measure to prevent strokes. The Respiratory segment develops and markets products for the assessment of pulmonary function. In all mainly business areas, Geratherm has patent-protected basic technologies at its disposal. We regard ourselves as a research-based medical products company with a clear focus on medical diagnostic devices that generate vital data. Geratherm shares have been listed in the Prime Standard segment of the Frankfurt Stock Exchange since the year 2000. Geratherm Medical continues to be represented in the German Entrepreneurial Index and in the German Healthcare Index. Geratherm Medical AG, Investor Relations Fahrenheitstraße 1, 98716 Geschwenda Tel. +49 (0)36205/98 111, E-Mail: [email protected] www.geratherm.com Emittent: Geratherm Medical AG, Fahrenheitstraße 1, 98716 Geschwenda Deutschland Tel. 036205/98 111 Fax: 036205/98 115 ISIN : DE 000 549 562 6 WKN : 549 562 Börsen : Frankfurter Wertpapierbörse /Geregelter Markt/Prime Standard Börse: Freiverkehr in Berlin-Bremen, Düsseldorf, Hamburg, München, Stuttgart 20.03.2014 DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: Geratherm Medical AG Fahrenheitstraße 1 98716 Geschwenda Germany Phone: +49 (0)36205 98-0 Fax: +49 (0)36205 98-1 15 E-mail: [email protected] Internet: www.geratherm.com ISIN: DE0005495626 WKN: 549562 Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, München, Stuttgart End of Announcement DGAP News-Service ---------------------------------------------------------------------------


Die wichtigsten Finanzdaten auf einen Blick
  2015 2016 2017 2018 2019 2020 2021e
Umsatzerlöse1 21,59 21,41 21,03 21,52 19,85 27,47 28,90
EBITDA1,2 3,42 3,71 1,77 2,80 2,35 4,35 5,00
EBITDA-Marge3 15,84 17,33 8,42 13,01 11,84 15,84 17,30
EBIT1,4 2,53 2,54 0,63 1,99 1,05 3,04 3,60
EBIT-Marge5 11,72 11,86 3,00 9,25 5,29 11,07 12,46
Jahresüberschuss1 2,39 2,25 0,22 0,83 0,29 1,90 2,50
Netto-Marge6 11,07 10,51 1,05 3,86 1,46 6,92 8,65
Cashflow1,7 3,77 0,79 2,47 1,35 1,54 3,92 4,55
Ergebnis je Aktie8 0,55 0,45 0,14 0,23 0,11 0,41 0,48
Dividende8 0,50 0,50 0,47 0,40 0,25 0,40 0,42
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2020 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: BDO

INVESTOR-INFORMATIONEN
©boersengefluester.de
Geratherm Medical
WKN Kurs in € Einschätzung Börsenwert in Mio. €
549562 9,220 Kaufen 45,64
KGV 2022e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
13,76 25,11 0,55 27,69
KBV KCV KUV EV/EBITDA
2,54 11,66 1,66 10,30
Dividende '20 in € Dividende '21e in € Div.-Rendite '21e
in %
Hauptversammlung
0,40 0,42 4,56 11.06.2021
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
20.05.2021 25.08.2021 24.11.2021 28.04.2021
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-5,60% -16,11% -15,41% -17,68%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu Geratherm Medical AG  ISIN: DE0005495626 können Sie bei DGAP abrufen

Medtech , 549562 , GME , XETR:GME